Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer

TL;DR

This paper reviews recent advances in using EGFR-targeted therapies before and after surgery for early-stage non-small cell lung cancer with EGFR mutations.

Contribution

The paper provides a novel synthesis of clinical trial outcomes and discusses key issues in perioperative targeted therapy for EGFR-mutated NSCLC.

Findings

EGFR-TKIs have shown significant progress in postoperative adjuvant therapy for EGFR-mutated NSCLC.

Neoadjuvant targeted therapy is emerging as a promising approach to improve outcomes in resectable NSCLC.

Guidelines now recommend EGFR-TKIs for perioperative treatment based on recent clinical trial evidence.

Abstract

肺癌在全球范围内仍是导致癌症死亡的首要原因，非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌的主要病理类型，占80%左右。在所有NSCLC患者中，约30%初诊时为可切除的早中期NSCLC。近期表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs）在EGFR突变可切除的NSCLC围手术期辅助靶向治疗中取得重大突破，并被指南推荐应用于临床。本文在总结EGFR突变可切除NSCLC围手术期辅助靶向治疗临床研究进展的基础上，针对临床研究中的关键问题进行探讨。

Summary of clinical trials of postoperative adjuvant targeted therapy

Summary of clinical trials of neoadjuvant targeted therapy